Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$47.62 USD
-1.35 (-2.76%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $47.70 +0.08 (0.17%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.62 USD
-1.35 (-2.76%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $47.70 +0.08 (0.17%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Zacks News
Earnings Estimates Moving Higher for Corcept (CORT): Time to Buy?
by Zacks Equity Research
Corcept (CORT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View
by Zacks Equity Research
CORT beats on both earnings and sales in the third quarter of 2024. The company increases the revenue guidance for 2024. Stock falls in after-hours trading.
Corcept Therapeutics (CORT) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 51.85% and 6.07%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Buy Low-Beta Stocks JD, SKWD, CORT, PRA to Beat Election Uncertainty
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. JD, SKWD, CORT & PRA are well-poised to gain.
Zacks.com featured highlights Idaho Strategic, Qifu, Sezzle, Corcept and FinWise
by Zacks Equity Research
Idaho Strategic, Qifu, Sezzle, Corcept and FinWise have been highlighted in this Screen of The Week article.
5 Stocks With Recent Price Strength to Tap Wall Street Rally
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IDR, QFIN, SEZL, CORT, FINW.
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSML
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSML
Strength Seen in Corcept (CORT): Can Its 5.5% Jump Turn into More Strength?
by Zacks Equity Research
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Wall Street Analysts See a 43.01% Upside in Corcept (CORT): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Corcept (CORT) points to a 43% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Corcept (CORT) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Implied Volatility Surging for Corcept Therapeutics (CORT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Corcept Therapeutics (CORT) stock based on the movements in the options market lately.
Zacks.com featured highlights include Atour Lifestyle, Vertiv, Corcept Therapeutics, Qifu Technology and ADMA Biologics
by Zacks Equity Research
Atour Lifestyle, Vertiv, Corcept Therapeutics, Qifu Technology and ADMA Biologics are part of the Zacks Screen of the Week article.
5 Stocks With Recent Price Strength Amid October Volatility
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ATAT, VRT, CORT, QFIN, ADMA.
Zacks.com featured highlights include Corcept Therapeutics, Abercrombie & Fitch and HCI Group
by Zacks Equity Research
Corcept Therapeutics, Abercrombie & Fitch and HCI Group have been highlighted in this Screen of The Week article.
3 Strong Buy Momentum Stocks as Bull Market Nears 2-Year Mark
by Tirthankar Chakraborty
Stocks like Corcept Therapeutics, Abercrombie & Fitch and HCI Group have been selected as the momentum picks for the day using the Driehaus strategy.
Here's Why Investors Should Consider Buying Corcept Stock Now
by Zacks Equity Research
Here, we are discussing some reasons why investing in CORT stock now may turn out to be a prudent move.
Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alnylam Pharmaceuticals (ALNY) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.
Here's Why Momentum in Corcept (CORT) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?
by Zacks Equity Research
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Do Options Traders Know Something About Corcept (CORT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.
Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept Shares Rise More Than 45% in Six Months: Here's Why
by Zacks Equity Research
CORT's Cushing's syndrome drug, Korlym, has been performing well. The NDA for lead candidate, relacorilant, in Cushing's syndrome will be filed shortly.